-transparent.png){kind=logo}
3'-Deamino-3'-(4-morpholinyl)adriamycin (MRA) and 3'-deamino-3'(3-cyano-4-morpholinyl)adriamycin (MRA-CN) were compared with adriamycin (ADR) in ADR-sensitive (P388/S) and -resistant (P388/ADR) murine leukemia cell lines with respect to cytotoxicity and cellular accumulation. MRA is only two- to threefold more cytotoxic to P388/S in culture than ADR, whereas MRA-CN is 500-fold more cytotoxic than ADR to this cell line. Yet both MRA and MRA-CN retain their potency against P388/ADR in spite of a 150-fold decrease in potency for ADR. The observed noncross-resistance of both MRA and MRA-CN in P388/ADR correlates with their increased cellular uptake and retention relative to ADR and the inability of P388/ADR to exclude these analogs as readily as it does ADR. The decreased uptake of MRA and MRA-CN in P388/ADR relative to P388/S (1.5 to 2.0-fold), the increased efflux, and the ability of verapamil to enhance cellular uptake of these analogs in P388/ADR, as it does with ADR, all indicate that the mechanism of ADR-resistance effects ADR and the morpholino analogs in a similar manner but to far different extents. The potent cytotoxicity of MRA-CN appears to be related to strong cellular interactions of the drug with macromolecules that are characterized by its nonextraction from cells by chloroform: methanol or 10 M urea and may therefore represent covalent binding.
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
January 1983,
Oncology,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
January 1978,
Biochemical pharmacology,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
June 1982,
Journal of the National Cancer Institute,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
December 1994,
International journal of oncology,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
April 1986,
International journal of peptide and protein research,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
January 1987,
Anticancer research,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
November 1984,
Cancer research,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
May 1987,
Cell biology international reports,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
January 1990,
Neoplasma,
D G Streeter, and
J S Johl, and
G R Gordon, and
J H Peters
April 1989,
Tumori,
